<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00164151</url>
  </required_header>
  <id_info>
    <org_study_id>F38-23</org_study_id>
    <nct_id>NCT00164151</nct_id>
  </id_info>
  <brief_title>A Comparison of the Efficacy and Safety of HalfLytely Vs Visicol Prior To Colonoscopy.</brief_title>
  <official_title>A Comparison of the Efficacy and Safety of Two Bowel Preparations: HalfLytely® (2L NuLYTELY and 20 mg Bisacodyl), and Visicol™ Prior To Colonoscopy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Braintree Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Braintree Laboratories</source>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the efficacy and safety of HalfLytely as compared
      to Visicol as bowel preparations before colonoscopic examination.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2001</start_date>
  <primary_completion_date type="Actual">May 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bowel preparation success: preparation rated as &quot;good&quot; or &quot;excellent&quot; by the blinded investigator.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: review of preparation symptoms, adverse events and laboratory testing.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient acceptance</measure>
  </secondary_outcome>
  <enrollment>60</enrollment>
  <condition>Colonoscopy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HalfLytely</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Visicol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female outpatients who are undergoing colonoscopy for routinely accepted
             indications, Evaluation of BE results, GI bleeding, Anemia of unknown etiology,
             Neoplastic disease surveillance, Endosonography, Inflammatory bowel disease (except as
             noted below), Unknown diarrhea etiology, Polypectomy, Laser therapy, Foreign body
             removal and decompression (except as noted below).

          -  18 years of age or older.

          -  Otherwise in good health, as determined by physical exam and medical history.

          -  If female, and of child-bearing potential, is using an acceptable form of birth
             control (hormonal birth control, IUD, double-barrier method, or vasectomized spouse).

          -  Subjects with electrolyte abnormalities such as hypernatremia, hyperphosphatemia,
             hypokalemia, or hypocalcemia must have them corrected prior to study participation.

          -  Subject has read and signed the written informed consent document prior to study
             participation.

        Exclusion Criteria:

          -  Subjects with known or suspected bowel perforation or obstruction, severe inflammatory
             bowel disease, ileus, acute alimentary tract surgery, significant gastroparesis or
             gastric outlet obstruction, appendicitis, gastric retention, toxic colitis, toxic
             megacolon, or massive and/or abnormal rectal bleeding.

          -  Subjects with impaired consciousness that predisposes them to pulmonary aspiration.

          -  Subjects with uncontrolled cardiovascular disease.

          -  Subjects with congestive heart failure.

          -  Subjects with unstable angina pectoris.

          -  Subjects with ascites.

          -  Subjects with renal insufficiency.

          -  Subjects who, in the opinion of the investigator, should not be included in the study
             for any reason, including inability to follow study procedures.

          -  Subjects who have participated in an investigational clinical, surgical, drug, or
             device study within the past 30 days.

          -  Subjects who are pregnant or lactating.

          -  Subjects who are allergic to polyethyleneglycol.

          -  Subjects who are allergic to sodium phosphate salts.

          -  Subjects who are currently taking, or plan to take, other sodium phosphate- containing
             products, such as enemas or non-prescription liquid purgatives.

          -  Subjects with pre-existing electrolyte disturbances, such as dehydration, or those
             secondary to the use of diuretics.

          -  Subjects who are taking drugs that may affect electrolyte levels.

          -  Subjects receiving non-study laxatives, antacids and prokinetic agents during the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Charles Brady, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Health Science Center San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>February 6, 2013</last_update_submitted>
  <last_update_submitted_qc>February 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2013</last_update_posted>
  <keyword>colonoscopy preparation</keyword>
  <keyword>prep</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

